ArticleJournal of drug delivery science and technology2020
A pH sensitive thiolated β-cyclodextrin-modified nanoporous gold for controlled release of doxorubicin.
Article in Journal of drug delivery science and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Preparation and Release of pH-Sensitive β-Cyclodextrin Derivative Micelles Loaded with Paclitaxel.Polymers · 2022Article
- Co-delivery of doxorubicin and conferone by novel pH-responsive β-cyclodextrin grafted micelles triggers apoptosis of metastatic human breast cancer cells.Scientific reports · 2021Article
- Nanoporous Gold Monolith for High Loading of Unmodified Doxorubicin and Sustained Co-Release of Doxorubicin-Rapamycin.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This article reports a novel thiolated β-cyclodextrin (HS-β-CD) modified nanoporous gold (NPG) wire for pH sensitive delivery of doxorubicin (DOX) in controlled manner. Nanoporous gold is a versatile material because of its three-dimensional nanoscale network of pores, facile surface functionalization, biocompatibility, and high capacity for the DOX payload. HS-β-CD can form supramolecular inclusion complexes with DOX affording the possibility of altering the controlled release behavior. DOX is one of the most potent anti-tumor drugs used in the treatment of different cancers. The binding of HS-β-CD and DOX was examined using UV-Vis spectroscopy. The prepared NPG structure exhibited excellent properties for controlled drug release outlining the potential of a pH sensitive drug implant for biomedical applications. This delivery system could improve local targeting of the drug as well as alter the rate of release of DOX near tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.